Teva to Present at the 29th Annual J.P. Morgan Healthcare Conference

JERUSALEM--(BUSINESS WIRE)-- Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) will host a live audio webcast at the 29th Annual J.P. Morgan Healthcare Conference with Eyal Desheh, CFO, Teva Pharmaceutical Industries Ltd. and William Marth, President & CEO, Teva Pharmaceuticals - Americas, presenting on Tuesday, January 11, 2011 in San Francisco.

 

What:

Teva Presentation at the 29th Annual J.P. Morgan Healthcare Conference
 

Who:

Eyal Desheh, CFO, Teva Pharmaceutical Industries and
William Marth, President & CEO, Teva Pharmaceuticals – Americas
 

When:

Tuesday, January 11th, 2011, at 1:30 PM Pacific Standard Time
 

Where:

www.tevapharm.com/financial/ or

http://jpmorgan.metameetings.com/webcasts/healthcare11/directlink?ticker=TEVA

 

How:

Live over the Internet – log on to the Web at the address above and register for the event (approx. 10 minutes before). An archive of the webcast will also be available on Teva's website.

 

About Teva

Teva Pharmaceutical Industries Ltd. (NASDAQ:TEVA) is a leading global pharmaceutical company, committed to increasing access to high-quality healthcare by developing, producing and marketing affordable generic drugs as well as innovative and specialty pharmaceuticals and active pharmaceutical ingredients. Headquartered in Israel, Teva is the world's largest generic drug maker, with a global product portfolio of more than 1,250 molecules and a direct presence in approximately 60 countries. Teva's branded businesses focus on neurological, respiratory and women's health therapeutic areas as well as biologics. Teva's leading innovative product, Copaxone®, is the number one prescribed treatment for multiple sclerosis. Teva employs more than 40,000 people around the world and reached $13.9 billion in net sales in 2009.



CONTACT:

IR:
Teva Pharmaceutical Industries Ltd.
Elana Holzman, 972 (3) 926-7554
or
Teva North America
Kevin C. Mannix, 215-591-8912
or
PR:
Teva Pharmaceutical Industries Ltd.
Yossi Koren, 972 (3) 926-7687
or
Teva North America
Denise Bradley, 215-591-8974

KEYWORDS:   United States  North America  California  New York  Middle East  Israel

INDUSTRY KEYWORDS:   Health  Pharmaceutical

MEDIA:

Suggested Articles

While Lilly's 2018 launch Emgality is approved to prevent migraines, Reyvow is intended to treat them as they occur.

ICER's new draft review of RA drugs takes a different approach, reflecting how physicians treat the disease and the time horizon that's considered.

Johnson & Johnson is facing multibillion-dollar liabilities in thousands of talc and opioid cases. But that's not such a bad thing, one analyst said.